StreetInsider.com  Sep 30  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sanofi+%28SNY%29%2C+Regeneron+%28REGN%29+Report+Dupilumab+Phase+2a+Met+Primary%2C+Secondary+Endpoints/9869338.html for the full story.
Market Intelligence Center  Sep 26  Comment 
Regeneron Pharmaceuticals Inc (REGN) presents a trading opportunity that offers a 5.80% return in just 57 days. A covered call on Regeneron Pharmaceuticals at the $355.00 level expiring on Nov. '14 offers an assigned return rate of 5.80% or...
Motley Fool  Sep 23  Comment 
Bayer and Regeneron Pharmaceuticals get three Eylea approvals in as many months.
SeekingAlpha  Sep 21  Comment 
By Abba's Aces: I recently closed my position in United Rentals, Inc. (NYSE:URI) from my growth portfolio because I felt that I had a pretty good profit at the time and wanted to lock up some gains. I ended up buying shares of Regeneron...
Benzinga  Sep 18  Comment 
In a report published Thursday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Regeneron Pharmaceuticals Inc (NASDAQ: REGN), but removed the $310.00 price target. In the report, Morgan Stanley noted, “We hosted...
SeekingAlpha  Sep 18  Comment 
By Abba's Aces: I recently closed my position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) from my growth portfolio because I felt that I had a pretty good profit at the time and wanted to lock up some gains. I ended up buying shares of...
Market Intelligence Center  Sep 17  Comment 
The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artifical Intelligence Center found a trading opportunity with Regeneron Pharmaceuticals Inc (REGN) that should provide a 5.82% return in just 66 days. Sell one...
StreetInsider.com  Sep 16  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Regeneron+%28REGN%29+Receives+IBT+Designation+from+FDA+for+EYLEA/9834821.html for the full story.
Jutia Group  Sep 16  Comment 
[PR Newswire] - TARRYTOWN, N.Y., Sept. 16, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted EYLEA® (aflibercept) Injection Breakthrough Therapy...
SeekingAlpha  Sep 8  Comment 
By Kanak Kanti De: In a year that has seen biotechnology stocks struggle in general, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is an exception. Shares of the biotechnology company are up more than 25% so far this year. The gains, though, do not...


Since its inception in 1988, Regeneron Pharmaceuticals, Inc. (REGN) has operated as a research and development (R&D) company engaged in the development of drugs for the treatment of various diseases. Regeneron's goal is to become a fully integrated biopharmaceutical company by commercializing these drugs. The company has advanced a few of its pipeline drugs into clinical stage development. The leading drug programs in this regard are IL-1, for inflamatory disease, and VEGF, for cancer and eye diseases. Revenues consist of R&D collaboration payments from development partner Sanofi-Aventis and contract manufacturing payments from pharmaceutical giant Merck for a pediatric vaccine. Manufacturing agreement expired in October 2006. From 2007, revenue will mainly derive from collaboration with Sanofi-Aventis and Bayer and from technology transfers.

Regeneron is cururently based in Tarrytown, NY. In December 2006, the company signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods. The new facilities will be constructed by BioMed Realty Trust over the next two years.

The Platform Techonology

Regeneron's most important propriatary technology is Trap Technology utilizing engineered antibody techniques. The decoy receptors (Traps) are composed of fusions between two distinct receptor components and a portion of an antibody molecule called the "Fc region", resulting in the generation of blockers with markedly increased affinity over that offered by single component reagents. Regeneron has applied this proprietary Trap technology to create a number of therapeutic candidates such as the IL-1 Trap and the VEGF Trap. The company also developed Velocigene/VelocImmune Technology which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki